AU2002330088B2 - Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy - Google Patents

Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy Download PDF

Info

Publication number
AU2002330088B2
AU2002330088B2 AU2002330088A AU2002330088A AU2002330088B2 AU 2002330088 B2 AU2002330088 B2 AU 2002330088B2 AU 2002330088 A AU2002330088 A AU 2002330088A AU 2002330088 A AU2002330088 A AU 2002330088A AU 2002330088 B2 AU2002330088 B2 AU 2002330088B2
Authority
AU
Australia
Prior art keywords
suramin
dose
patient
agent
bsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002330088A
Other languages
English (en)
Other versions
AU2002330088A1 (en
Inventor
Jessie L.-S. Au
M. Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002330088A1 publication Critical patent/AU2002330088A1/en
Application granted granted Critical
Publication of AU2002330088B2 publication Critical patent/AU2002330088B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002330088A 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy Ceased AU2002330088B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32470401P 2001-09-24 2001-09-24
US60/324,704 2001-09-24
PCT/US2002/030210 WO2003026574A2 (en) 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Publications (2)

Publication Number Publication Date
AU2002330088A1 AU2002330088A1 (en) 2003-06-26
AU2002330088B2 true AU2002330088B2 (en) 2009-09-03

Family

ID=23264730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002330088A Ceased AU2002330088B2 (en) 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Country Status (9)

Country Link
US (2) US20040180955A1 (enExample)
EP (1) EP1429713A4 (enExample)
JP (1) JP2005508322A (enExample)
KR (1) KR20040062546A (enExample)
CN (1) CN100441176C (enExample)
AU (1) AU2002330088B2 (enExample)
CA (1) CA2461227C (enExample)
IL (1) IL161036A0 (enExample)
WO (1) WO2003026574A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007065016A2 (en) * 2005-12-02 2007-06-07 Au Jessie L S Methods and compositions to improve activity and reduce toxicity of stents
KR20140098185A (ko) * 2007-07-30 2014-08-07 아디아 바이오사이언스즈 인크. 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
PH12018501678B1 (en) 2011-08-30 2022-08-10 Astex Pharmaceuticals Inc Decitabine derivative formulations
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
EP3316685A4 (en) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilized Pharmaceutical Compositions
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
JP2022145629A (ja) * 2021-03-18 2022-10-04 学校法人産業医科大学 スラミンを含む組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597830A (en) * 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
ES2248847T3 (es) * 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
ATE241993T1 (de) * 1997-03-11 2003-06-15 Aeterna Lab Inc Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
AU780454B2 (en) * 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Song S. et al. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Research, 15 August 2001. vol. 61, pages 6145-6150.. *
Tu, S. et al. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clinical Cancer Research, May 1998. vol. 4, pages 1193-1201. *

Also Published As

Publication number Publication date
HK1074167A1 (zh) 2005-11-04
EP1429713A4 (en) 2007-08-08
EP1429713A2 (en) 2004-06-23
CA2461227A1 (en) 2003-04-03
CN1589138A (zh) 2005-03-02
CA2461227C (en) 2012-05-15
CN100441176C (zh) 2008-12-10
WO2003026574A3 (en) 2004-04-15
JP2005508322A (ja) 2005-03-31
US8580857B2 (en) 2013-11-12
WO2003026574A2 (en) 2003-04-03
KR20040062546A (ko) 2004-07-07
IL161036A0 (en) 2004-08-31
US20110142794A1 (en) 2011-06-16
US20040180955A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
US8580857B2 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
Choy et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non–small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)
CN100363004C (zh) 喹唑啉衍生物zd6474组合吉西他滨在制备药物中的用途
EP3038647B1 (en) Combination therapy for the treatment of glioblastoma
Pipas et al. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma
Weppelmann et al. Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation
NZ539514A (en) Combination product of inhibitor of the Src family of non-receptor tyrosine kinases and gemcitabine
TW200838875A (en) Combination therapy with angiogenesis inhibitors
Cerbone et al. Results from a phase I study of lapatinib with gemcitabine and cisplatin in advanced or metastatic bladder cancer: EORTC Trial 30061
AU2002330088A1 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
CA3056813A1 (en) Combination therapy for the treatment of ovarian cancer
JP2008501654A (ja) シスプラチンとｅｇｆｒ阻害剤を用いた治療
Mason et al. Biology-based combined-modality radiotherapy: workshop report
TW200404532A (en) Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
Ledwitch et al. Taxol: efficacy against oral squamous cell carcinoma
Akerley et al. Induction Paclitaxel/Carboplatin Followed by Concurrent Chemoradiation Therapy for Unresectable Stage III Non–Small-Cell Lung Cancer: A Limited-Access Study (CALGB 9534)
Kelsen et al. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5‐fluorouracil and levamisole after resection of high risk colon cancer
US20250387643A1 (en) Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy
Sano et al. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model
Dodd et al. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma
TW201717926A (zh) 用於治療尤文氏家族腫瘤(ewing family tumors)的組成物及方法
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Helsing et al. Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial
Kheradpour et al. A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia
HK1074167B (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired